Dateline City:
SAN FRANCISCO
Overall Response Rate of 66 Percent Observed in KEYTRUDA-treated Patients Whose Cancer Progressed on Brentuximab Vedotin
Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-087)
SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today early study findings demonstrating that KEYTRUDA (pembrolizumab),
the companys anti-PD-1 therapy, achieved an overall response rate of 66
percent, as assessed by International Harmonization Project response
criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure
patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose
disease progressed on or after treatment with brentuximab vedotin.
Language:
English
Contact:
Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more